Business
Hemostemix Announces its 10th Publication: A Molecular Strategy for the Treatment of Heart Failure: Response to BioCardia's Cardiamp Heart Failure Trial
Calgary, Alberta--(Newsfile Corp. - July 3, 2025) -   Hemostemix Inc.  (TSXV: HEM) (OTC...
About this update from Hemostemix Inc
[{"type":"text","content":"Hemostemix Announces its 10th Publication: A Molecular Strategy for the Treatment of Heart Failure: Response to BioCardia's Cardiamp Heart Failure TrialCalgary, Alberta--(Newsfile Corp. - July 3, 2025) -  Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is proud to share the Journal of Biomedical Research and Environmental Science published Autologous Angiogenic Cell Precursors-A Molecular Strategy for The Treatment of Heart Failure: Response to BioCardia's Cardiamp HF Trial.Recent research has revealed the importance of choosing the right patients and the right type of stem cell to effectively treat inflammatory heart disease. Many traditional approaches using bone marrow-derived cells have failed in large trials, especially when applied broadly to patients with different forms of heart failure. However, Hemostemix's ACP-01 stands apart, due to its specific molecular characteristics and its ability to precisely target the root causes of non ischemic dilated cardiomyopathy (DCM): inflammation, fibrosis, and poor blood flow.In Hemostemix' two earlier studies of DCM patients, cardiac function as measured by left ventricle ejection fraction percent (LVEF%) increased by up to 47.1% following one treatment (Stem Cell Research & Therapy, November 2023), with the most marked improvements observed in patients with severe dilated cardiomyopathy (LVEF% < 20%).Study/Case SeriesPatient TypeBaseline LVEFPost-ACP-01 LVEFTime FrameKey Outcomes Previous Dilated Cardiomyopathy Study Results for ACP-01Hemostemix Phase 1 DataIschemic/Non-ischemic18-25%35-45%3-12 monthsImproved NYHA class, 6MWT Compassionate Use CasesEnd-stage DCM≤20%↑ by 10-25% points6-12 monthsReduction in CHF symptom A Molecular Strategy for the Treatment of Heart FailureThe Science of ACP-01: Targeted Repair at the Cellular LevelACP-01 is made from autologous cells, taken from the patient's blood, reducing the risk of rejection or immune attack-response. ACP-01 consists of angiogenic cell precursors, which are biologically programmed to migrate to the site of injury, attract NK cells to reduce inflammation and fibrosis, and drive angiogenesis to improve microcirculation, Migrate Precisely to Areas of InjuryUnlike other cell therapies, ACP-01 maintains high expression of CXCR4, a receptor that guides cells to injured tissue by ...